Background. Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas with minimal therapeutic opportunities. We observed that lipid droplets (LDs) accumulate in human MPNST cell lines and in primary human tumor samples. The goal of this study was to investigate the relevance of lipid metabolism to MPNST survival and as a possible therapeutic target.
Malignant peripheral nerve sheath tumor (MPNST) is a rare soft tissue sarcoma that is highly invasive and lethal unless complete resection is feasible. Half of MPNSTs arise spontaneously in adults (sporadic MPNSTs), and 50% of MPNSTs are associated with neurofibromatosis type 1 (NF1); the lifetime risk of MPNST in NF1 patients is 8% -13%. 1, 2 Chemotherapy and radiation have minimal advantage in MPNST 3 ; therefore, alternative therapies are urgently needed.
MPNSTs are nerve-associated soft tissue sarcomas. MPNST cells express markers characteristic of the neural crest cells from which they are believed to arise. 4 -6 Schwann cell progenitors from the neural crest differentiate into nerve glial cells (Schwann cells). Neural crest cells have considerable self-renewal and differentiation potential, while progenitors identified after the establishment of the dorsal root ganglia and peripheral nerve have more limited self-renewal and differentiation potential. 7, 8 We hypothesized that shared features of neural crest cells in defined MPNST cells could be exploited as MPNST therapies.
MPNSTs have a complex karyotype with amplifications and deletions of many alleles. 9 Sporadic MPNST can have mutations in the NF1 gene or other Ras pathway genes, confirming reliance on the Ras pathway in this tumor type. 10 Inhibition of MEK (mitogen-activated protein kinase kinase) downstream of Ras signaling evoked a modest reduction in growth of human MPNST xenografts. 11 The mammalian target of rapamycin (mTOR) signaling pathway is also activated in MPNST, and blocking mTOR signaling with rapamycin or its analogs also transiently delayed tumor growth. 12, 13 Several other signaling pathways have been tested over the past decade, but there have been no therapeutics demonstrated to target MPNSTs. Here we began to identify targetable molecules by studying metabolism of MPNST cells.
We focused our efforts on lipid metabolism, as increased lipogenesis is a hallmark of many human cancers and has been associated with poor prognosis in breast, prostate, and colon cancer. 14, 15 Two hallmarks of altered lipid metabolism are the increased accumulation of lipid bodies/droplets in cell bodies and an overexpression of enzymes involved in fatty acid synthesis (FASN). Inhibitors of FASN are potential targets for antineoplastic interventions and chemoprevention. 16 Animal cells have 2 sources of fatty acids (FAs), exogenously derived (dietary) FAs and endogenously synthesized FAs. The biosynthesis of the latter is catalyzed by the multifunctional, homodimeric enzyme FASN. 15, 17 FASN synthesizes long-chain FAs from acetyl-CoA using malonyl-CoA and NADPH. Cerulenin, a natural antibiotic product of the fungus Cephalosporium caerulens, 18 inhibits FASN activity and can cause apoptotic death of cancer cells in vitro. 19, 20 C75, a synthetic cerulenin analog, is also a potent FASN inhibitor 21 cytotoxic to cancer cells in vitro, and shows significant in vivo antitumor activity against some human cancer xenografts. 22, 23 We show here the importance of lipid metabolism in MPNST. Lipid droplets (LDs) accumulate in human MPNST cells in vitro and in human tumor samples, consistent with the stored lipids that we identify in migrating neural crest cells. Inhibiting FASN in vitro caused cytotoxic effects on MPNSTs and significantly delayed tumor growth in a human MPNST xenograft model. Thus, targeting lipid metabolic pathways could be a potential therapeutic strategy in MPNST.
Materials and Methods

Cell Lines and Reagents
MPNST cell lines STS26T, ST8814, ST88-3, S462, T265p21, 90-8, immortalized human Schwann cells (iHSCs), and normal human Schwann cells from autopsy specimens were obtained and maintained as described. 24 -26 Postmigratory neural crest cells were isolated from mice on embryonic day (E) 8.5 and plated on poly-L-lysine + fibronectin-coated Labtech chamber slides (Nunc) as described. 27 
BODIPY Staining
MPNST cells cultured in 8-well chambered slides were washed with ice cold phosphate buffered saline (PBS) and fixed in 4% paraformaldehyde for 5 min at room temperature (RT). After a rinse in PBS the cells were incubated with BODIPY 493/503 (boron-dipyrromethene; Life Techonologies #D-3922) at 10 ng/mL in dimethyl sulfoxide (DMSO) for 15 min in the dark at RT. After rinses in PBS, cells were mounted in Fluoromount-G and imaged using the Zeiss Axiovert 200M microscope.
Oil Red O Staining
Sections were fixed in 10% formalin for 10 min, then rinsed 3 times in 1× PBS. Slides were then placed in oil red O (ORO) solution for 10 min, rinsed in tap water, and counterstained with hematoxylin for 1 min, per kit protocol (Abcam # ab150678). Sections were then mounted in Fluoromount-G and coverglassed.
Isolation and Sectioning of Mouse Embryos
Embryos were isolated from pregnant wild-type C57Bl/6 mice on E8.5-E15.5. Wnt-Cre enhanced green fluorescent protein (EGFP) embryos were from Jeff Robbins at Cincinnati Children's Hospital Medical Center (CCHMC). 27 Embryos were decapitated and placed in 4% paraformaldehyde for 12-24 h, transferred to 20% sucrose, and stored at 48C until embedding and freezing in optimal cutting temperature (OCT) medium. Serial sections (12 mM) were cut using a cryostat (Leica). Tissue sections at the level of the hind limbs were collected and stained with ORO to visualize neutral lipids and cholesteryl esters but not biological membranes. 28 
Tumor Samples
Human MPNST tumors were collected in accordance with institutional review board -approved protocols from discarded surgical specimens received from the Cincinnati Children's Hospital Bio Bank as flash frozen samples. Geneticaly engineered mouse (GEM)-PNST tumors from Nf1+/2/p53+/2 mutations in cis on mouse chromosome 11 (NPcis) have been described. 6 Xenograft tumors were obtained from nu/nu mice injected with the MPNST cell line STS26T, a non-NF1 (sporadic) MPNST cell line. 13 Unfixed tumors were embedded in OCT medium and frozen and 20-mM cryostat sections cut.
MPNST Xenograft and Drug Administration
The STS26T human MPNST xenograft model has been described. 13, 29 STS26T MPNST cells (1.8× 10 6 ) were injected subcutaneously, in Matrigel, into the flanks of 4-to 5-week-old female nu/nu mice (Harlan). Treatment began when measurable (250 mm 3 ) tumors developed. C75 was dissolved in DMSO at 100 mM and diluted further in Dulbecco's modified Eagle's medium (DMEM) for administration to mice at a dose of 40 mg/kg (first dose) and 30 mg/kg subsequently, once a week i.p. in 0.1 mL total volume as in previous studies. 30, 31 Controls were administered vehicle (DMSO/DMEM). Mice were weighed and their tumor volumes measured with digital calipers twice weekly until tumors reached 2500 mm 3 . Tumor volume was calculated by: L * W2 (p/6), where L is the longest diameter and W is the width. All experiments were conducted following the approved protocol of the Institutional Animal Care and Use Committee.
Lentiviral Transfection
MPNST cells were transduced with lentiviral particles at 50% -60% confluence. Short hairpin (sh)RNAs targeting FASN, acetylCoA carboxylase (ACC), and control (nontargeting) were from the Sigma-Aldrich TRC (The RNAi Consortium) library. The CCHMC Viral Vector Core produced virus using a 4-plasmid packaging system (http://www.cincinnatichildrens.org/research/div/ exphematology/translational/vpf/vvc/default.html). Lentiviral particles were incubated with MPNST cells in the presence of polybrene (8 mg/mL; Sigma) for 24 h, followed by selection in 2 mg/mL puromycin, which killed uninfected cells within 3 days.
Immunoblot
Cell lysates were created and western blotting conducted as described. 4 Membranes were probed with anti-FASN (Cell
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Signaling Technology #3189) and stripped to be reprobed with horseradish peroxidase (HRP) -conjugated anti -b-actin (Cell Signaling Technology #5125) as a loading control. Signals were detected using HRP-conjugated secondary antibodies (BioRad) and the Immobilon Western Chemiluminescent HRP Substrate system (Millipore #WBKLS0500).
Quantitative Real-Time PCR
Total RNA was isolated from cells using the RNeasy kit (Qiagen) and used as a template for cDNA synthesis (High-Capacity cDNA archive kit, Applied Biosystems) and quantitative real-time PCR (ABI 7500 Sequence Detection System) as described. 29 For FASN and ACC, prime time pre-validated quantitative PCR primer sets were used from Integrated DNA Technologies assay #Hs.PT.56a.20384174 and #Hs.PT.56a.513712.g (for ACC).
Immunohistochemistry
Ten-micrometer sections from cryoprotected frozen xenograft tumors were fixed in 10% formalin for 10 min and immunohistochemistry conducted as described. 29 We used rabbit anticleaved caspase-3 (1:8000; Cell Signaling #9661) and rabbit anti-Ki-67 (1:5000 NCL-Ki67-P; Novocastra). Subsequently, sections were stained with the LD stain ORO and hematoxylin. Sections were photographed on a Nikon Eclipse 80i bright field microscope. For nuclear staining, sections were incubated in 4 ′ ,6 ′ -diamidino-2-phenylindole (DAPI) (1:10 000; Sigma) for 5 min, rinsed in PBS 3 times, and coverglassed in Fluoromount-G (EM Sciences #17984-25).
In vitro Cytotoxicity Assays
MPNST cells were plated in quadruplicate in serum containing growth medium on 96-well plates at 500 cells/well/dose. Plates were incubated at 378C and 5% CO 2 . After 24 h, cells were treated with carrier, etomoxir (R&D Systems #4539), C75 (Tocris #2489), orlistat (Sigma #O4139), and Irgasan (Sigma #72779). The amount of cell growth was determined using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay using the Cell Titer 96 proliferation kit (Promega). Absorbance was read at 490 nm on a Spectramax M2 plate reader (Molecular Devices).
Cell Proliferation/Death Analysis
MPNST cells at 60%-70% confluency were transduced with lentivirus, puromycin selected, and plated at day 3 post infection in 8-well chamber slides in DMEM/10% fetal bovine serum. The next day, cells were incubated with bromodeoxyuridine (BrdU) (BD Pharmingen #550891) 10 mM in cell culture medium for 15 min at 378C, rinsed with 1× PBS followed by a distilled (d)H 2 O rinse, and fixed with 4% paraformaldehyde (in 1× PBS) for 10 min at RT, then with 2N HCl/PBS containing 0.5% Triton and heated to 378C for 30 min, then neutralized with 0.1 M borate buffer (pH 8.5) for 5 min. Slides were washed in dH 2 O thrice. Blocking was with 10 mg/mL bovine serum albumin -PBS-0.1% Triton for 15 min. Incubation was overnight in antiBrdU (1:500; Abcam # ab6326) or rabbit anti-cleaved caspase-3 (Asp175) (1:200; Cell Signaling #9661). The slides were washed in PBS, then incubated for 2 h at RT in Alexa-488 anti-rat (A11006) or Alexa-647 anti-rabbit (A21244; Invitrogen) at 1:500 in blocking buffer. Cells were stained with DAPI; washed in PBS, then dH 2 O; and mounted in Fluoromount-G. Immunolabeled cells were visualized using a Zeiss Axiovert 200 M microscope. Antigen-positive cells were quantified from 5 fields/well for each treatment and plotted as percent of total DAPI+ nuclei per field.
Oxygen Consumption Rate Measurements
Cells (3000 cells/well) were plated into 96-well plates (Flux pack of XFe96, Seahorse Biosciences #102416-001) in 80 mL normal cell culture medium at 378C, 5% CO 2 overnight. The next day, after 2 rinses with 1× PBS, the medium was changed to extracellular flux minimal assay medium (Seahorse Biosciences #102353-100SB) supplemented with 1× GlutaMAX (Gibco #35050-079), 10 mM glucose (Sigma #G8769), and 0.5 mM carnitine (Sigma #C0158-5) and incubated at 378C without CO 2 for an hour. The steady-state (baseline) oxygen consumption rate (OCR) was measured with an XF96e Extracellular Flux Analyzer (Seahorse Biosciences). Etomoxir was added 10 min prior to OCR measurement. For OCR measurement in low lipid serum (LLS) (Hyclone #SH30855-03), cells were plated on day 0, medium changed to DMEM/LLS on day 1, and OCR measurement conducted on day 4.
Results
MPNSTs Show Lipid Droplet Accumulation in Their Cell Bodies
While observing MPNST cells by phase contrast microscopy, we noted the consistent presence of dark speckles in cell cytoplasm. To determine if these were LDs, we stained the MPNST cells with BODIPY 493/503. Imaging in phase and fluorescence and overlapping the images (Fig. 1A-C) confirmed that the dark spots observed were indeed LDs. We then stained cells from 7 human MPNST cell lines with ORO, a red bright field-neutral lipid stain. All MPNST cell lines exhibited LDs (Fig. 1E-G) , while normal human Schwann cells (Fig. 1D ) and iHSCs (data not shown) did not. To determine if LDs are present in MPNST tumors, we stained tissue sections. Surgically resected human MPNST tumors from 9 patients, and GEM-PNST tumors from the NPcis model (n ¼ 3; data not shown) were stained with ORO. There was considerable variability within each sample, but all showed ORO-positive regions (Fig. 1H-K) . Thus, primary human MPNSTs are enriched in LDs.
Migrating Neural Crest Cells Are Enriched in LDs During Development
MPNSTs are peripheral nerve sarcomas that may derive from peripheral nerve Schwann cell lineage cells or their multipotent neural crest cell precursors. Given that MPNSTs express transcripts and proteins characteristic of neural crest cells, we examined whether the cells of the migrating neural crest also show LD accumulation. The neural crest is a transient pluripotent cell population that delaminates from the dorsal neural tube. Migratory neural crest cells present in the trunk at E9 Patel et al.: Lipids in MPNST develop into Schwann cell precursors between E11 and E13 in mouse sciatic nerve, and into Schwann cells that ensheath nerve axons by birth. 32, 33 To enable identification of neural crest cells, we used a Wnt-Cre mouse model; breeding to a reporter mouse resulted in EGFP expression specifically in neural crest lineage cells in the trunk. 27 During neural crest cell migration at E9.5, precursors of peripheral nerve glia (Schwann cells), migrate through the ventrolateral migratory pathway adjacent to the neural tube. 34 At this time point we observed many EGFP-labeled cells in the migratory pathway that appeared to contain LDs ( Fig. 2A and B) . We also isolated postmigratory neural crest cells from E8.5 mouse neural tubes and tested for LDs. Consistent with the in vivo result, most or all cells that migrated from neural tubes showed abundant LDs in their cell bodies (Fig. 2C) .
In tissue sections from older embryos (E10.5 -E11.5; data not shown), progressively fewer ORO-positive cells were observed. By E12.5, most cells near the dorsal root ganglia and in the developing peripheral nerve were ORO negative (Fig. 2D-F ). Only in rare sections were occasional ORO-positive cells present, either near the dorsal root ganglia (data not shown) or within the developing peripheral nerve (Fig. 2G) . Thus, LDs are commonly present in migrating neural crest cells at E9.5, but not in the more mature embryonic Schwann cells present in the dorsal root ganglion or peripheral nerve at E12.5.
33
MPNSTs Use Endogenous and Exogenous Lipids
As MPNSTs accumulate LDs in cell lines and in tumor samples, we reasoned that they are used as a source of fuel to support proliferation. To examine if the lipids in LDs are being oxidized through the fatty acid oxidation (FAO) pathway, we used 2 FAO pathway inhibitors, etomoxir and perhexiline (Fig. 3A) , which are carnitine-palmitoyl transferase 1 (CPT1) inhibitors that block the rate-limiting step in FAO. Both inhibitors significantly decreased viability of MPNST cells (Fig. 3B, Supplementary Fig. S1A and S1B). Since FAO reduced viability, we reasoned that FAO inhibitors would also reduce O 2 consumption (OCR) if MPNST cells use molecular O 2 to metabolize LDs. Consistent with the reliance of MPNST cells on FAO, etomoxir caused a 20%-30% drop in OCR in all MPNST cell lines tested (Fig. 3C) . No toxicity was observed after etomoxir treatment, as judged in a cytotoxicity assay (MTS) after OCR reading (Fig. 3D) . Therefore, under normal cell culture conditions (DMEM with 10% fetal bovine serum), MPNST cell lines actively utilize FAO, possibly as a source of energy. 
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We hypothesized that LDs are stored in MPNST cells as a source of energy to be used when nutrients are limited. Since normal MPNST culture medium is rich in lipids, we reasoned that an LLS culture condition would test this hypothesis. MPNST (STS26T) cells cultured in the absence of exogenous lipids showed a depletion of LDs over 4 days of in vitro culture (Fig. 3E) . At this time point, MPNST cells cultured in LLS media also showed reduced viability (Fig. 3F) . To test if cells cultured in the absence of exogenous lipids were using FAO, OCR was measured in lipid-starved cells at day 4. A significant drop in OCR was observed in LLS cells treated with etomoxir versus untreated LLS cells (Fig. 3G,  Supplementary Fig. S1C ). Also, STS26T-LLS cells were more sensitive to etomoxir than were untreated STS26T cells (Fig. 3H) . The drop in OCR in the LLS cells on day 4 suggests that besides oxidizing exogenous lipids, MPNST cells also oxidize lipids synthesized de novo. Thus, MPNST cells rely on oxidation of lipids when nutrients are available, and they metabolize endogenous lipids under lipid-reduced conditions.
Fatty Acid Synthase Is Overexpressed in MPNST Cell Lines and Contributes to MPNST Cell Survival
The results presented above suggest that de novo synthesized lipids are also oxidized by MPNST cells. Therefore, we examined the expression of FASN, the only mammalian enzyme that makes de novo lipids in mammals. Indeed, FASN was significantly overexpressed in MPNST cell lines at the mRNA and protein levels versus normal human Schwann cells (Fig. 4A  and B) . To test whether FASN is important for MPNST viability, FASN expression was blocked with 2 validated lentiviral shRNAs. Three days after lentiviral infection of MPNST cells, FASN mRNA expression in FASN-silenced cells (shFASN) was reduced by 3.8-fold relative to cells expressing nontargeting shRNA (shNT) (Fig. 4C) . The expression of FASN was also reduced at the protein level, as confirmed by western blot analyses 4 days after lentiviral shRNA infection (Fig. 4D) . FASN inhibition significantly decreased MPNST viability (Fig. 4E ) and reduced metabolic activity as measured by MTS assay (Fig. 4E and F) . ShRNA targeting ACC, an upstream enzyme in the FAO pathway, also diminished MPNST cell metabolic activity and viability (Fig. 4F) . We next measured cell proliferation via BrdU incorporation and cell death via cleaved caspase-3 assay. ShFASN -MPNST cells showed a decrease in cell entry into S phase (proliferation) and increased cell death (apoptosis) compared with controls (Fig. 4G) . Thus, both FAO and de novo synthesis are necessary for survival of MPNST cells.
Inhibiting FASN Activity Reduces Cell Growth In vitro
To corroborate our genetic data suggesting a role for FASN activity in MPNST cell survival, we used drugs to inhibit FASN activity. 16 MPNST and iHSC lines were treated with 3 FASN inhibitors: C75, orlistat, and Irgasan. Each significantly reduced MPNST cell survival, with half-maximal inhibitory concentration (IC 50 ) 
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values for orlistat ranging from 9 mM (STS8814) to 25 mM (STS26T) and averaging 50 mM for Irgasan (Fig. 5B and C) . All 3 inhibitors also had a detrimental effect on the survival of the iHSCs (Fig. 5A -C) . However, iHSCs were consistently less sensitive than MPNST cells to each of the inhibitors. C75 is a widely used FASN inhibitor, studied in cancer models over the last decade. The IC 50 for MPNST cells exposed to C75 averaged 28 mM (Fig. 5A ), in accordance with reports of an average IC 50 of 20 mM for a subset of breast cancer cells 35 and 72 mM for lung cancer cell lines. 36 
Inhibiting FASN Activity Delays Tumor Growth In vivo
To test the effect of FASN inhibition on MPNST growth in vivo, we implanted STS26T MPNST cells into nu/nu mice and treated established tumors (250 mm 3 ) with C75 (n ¼ 14) or vehicle control (n ¼ 13). C75 was administered at 40 mg/kg on week 1, but some mice lost close to 10% body weight. We therefore dosed at 30 mg/kg on subsequent weeks. Higher levels of C75 are known to induce anorexia and significant weight loss, so this dosing schedule has been used before. 37, 38 Inhibiting FASN with C75 significantly delayed tumor growth compared with vehicle controls (Fig. 5D-F) . While the entire vehicle-treated mouse group reached 2500 mm 3 in 16-21 days (Fig. 5D ), C75-treated mice showed a 10-day delay (Fig. 5E ). Xenograft tumors were collected when they reached maximum allowable tumor burden. Paraffin sections of tumor showed apoptotic regions as detected by anti-cleaved caspase-3. These apoptotic regions contained cells with LDs, as detected via ORO (Fig. 5G) . Notably, these LD-rich, apoptotic domains surrounded the necrotic regions and were absent in actively dividing regions of tumor. Thus, targeting FASN is a potential therapeutic for MPNSTs, with modest single-agent efficacy.
Discussion
Here we have shown that lipid storage and mobilization are features of MPNST cells and neural crest cells. LDs were present in Our finding that LDs are present in MPNSTs and migrating neural crest cells is consistent with studies showing that human MPNST cells resemble neural crest cells in expression of the markers TWIST1, SOX9 PAX3, N-CAM, and p75. 4, 5 Their characteristic LD expression may be useful as a potential marker to distinguish MPNST from synovial sarcoma or other difficult to differentiate tumor types. In particular, we note that during development, most or all Schwann cell precursors and mature Schwann cells lack LDs. Indeed, our unpublished findings show that neurofibromas, which contain Schwann cells and Schwann cell precursor-like cells, lack LDs. Therefore, presence of LD-rich cells in a neurofibroma biopsy could potentially reflect regions of transformation to MPNST. These ideas will require verification.
We found that MPNSTs accumulate LDs in their cytoplasm and metabolize LDs on nutritional deprivation. Inhibition of FAO using several inhibitors showed a drop in OCR readings in these MPNST cells, indicating that these cells rely on FAO to meet their energy demands. The source of MPNST lipids (endogenous vs exogenous) in growing tumors remains to be determined. We show that under limiting exogenous lipid, addition of FASN inhibitor still causes a drop in OCR. This indicates that when exogenous lipid sources are reduced, MPNSTs rely on 
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Neuro-Oncologyoxidizing lipids in the LDs (which gradually disappear) but also channel endogenously produced lipids toward FAO when LDs are no longer available. The mechanisms underlying lipid mobilization in MPNST remain to be studied. Several complex mechanisms make lipids available for mitochondrial FAO; these include autophagic digestion of intracellular membranes and of LDs. 39 Transformed cells frequently exhibit specific alterations in metabolic activity, which supports their rapid proliferation and survival. A prominent metabolic alteration in cancer cells is an increase in glucose uptake and the use of aerobic glycolysis, called the Warburg effect. 40 In the past decade there has been a renewed interest in examining mitochondria-dependent functions in cancer. Citrate produced during glucose oxidation in mitochondria is the precursor of cellular lipids in the cytoplasm. In some contexts (as we found in MPNST cells), lipids reenter mitochondria for oxidation-a process important for the survival of these cells. Our results substantiate the importance of mitochondrial metabolism in MPNSTs for proliferation and growth. Besides oxidation in the mitochondria, lipids in LDs also undergo autophagy (macrolithophagy) during energy crisis, 41 and future studies will determine whether macrolithophagy contributes to MPNST survival.
The majority of adult mammalian tissues satisfy their lipid requirements through the uptake of free FAs from the blood. Fatty acid and cholesterol biosynthesis are restricted to select tissues, including liver and adipose and lactating breast tissues. However, reactivation of lipid biosynthesis is frequently observed in cancer. 16 We found this to be true for human MPNSTs, as evidenced by the overexpression of key enzymes of the de novo FASN pathway. Consequently, blocking FASN and ACC expression or activity significantly reduced the survival of MPNST cells. Inhibition of FASN in vivo in human MPNST xenograft models reduced sarcoma burden, consistent with previous observations in breast and prostate cancer xenograft models. 35 We posit that FASN inhibition, via lifestyle changes including a lipid-restricted diet or drugs, could be a component of MPNST therapy. However, because the current FASN inhibitors elicit anorexic effects, newer agents without this side effect are needed to test this idea. In addition, combinatorial therapies may be required for maximal benefit to patients. In conclusion, deregulated lipid metabolism is a novel therapeutic avenue for MPNST.
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